Journal: International Journal of Molecular Sciences

Article Title: Fraxin Attenuates Rheumatoid Arthritis by Regulating Macrophage Polarization and Inhibiting Fibroblast-like Synoviocyte Proliferation

doi: 10.3390/ijms27072946

Figure Lengend Snippet: Fraxin inhibited inflammation in Raw264.7 cells and FLs. ( A , B ) Effect of Fraxin on the cellular viability of Raw264.7 and FLs. ( C ) EC-50 of Fraxin (100 ng/mL) in Raw264.7 cells. ( D – F ) Flow cytometry analysis showing the polarization effect of Fraxin (100 ng/mL) on Raw264.7 cells. ( G – L ) RT-PCR analysis of Il6 , Tnfα , Il1b , Il10 , Cd206 , and Hspa8 in FLs treated with Fraxin. ( M – O ) Protein levels of p-NFκB-p65 and TNF-α were examined by Western blot in FLs. Fraxin low-dose group (Fraxin-L, 100 ng/mL), Fraxin high-dose group (Fraxin-H, 1 μg/mL). ## p < 0.01, ### p < 0.001 versus Ctrl; ** p < 0.01, *** p < 0.01 versus LPS.

Article Snippet: CD206 (A02285-2) and CD86 (BM4121) were purchased from Boster Biological Technology Co., LTD (Wuhan, China).

Techniques: Flow Cytometry, Reverse Transcription Polymerase Chain Reaction, Western Blot

Journal: International Journal of Molecular Sciences

Article Title: Fraxin Attenuates Rheumatoid Arthritis by Regulating Macrophage Polarization and Inhibiting Fibroblast-like Synoviocyte Proliferation

doi: 10.3390/ijms27072946

Figure Lengend Snippet: Fraxin improved the inflammatory microenvironment of the knee joint. ( A ) H&E staining of the knee joint. The area within the box represents the magnified region shown below. The red arrow points to meniscal injury, the blue arrow points to synovial thickening, and the green arrow points to synovial inflammatory pannus. ( B ) Knee joint staining with saffron solid green. ( C , D ) CD206 and CD86 immunofluorescence staining in the synovium. ( E ) The pathology score from H&E staining. ( F , G ) Quantitative analysis of CD206 and CD86 immunofluorescence staining. ( H ) Serum levels of IL-6 were analyzed by ELISA. ( I ) Serum levels of TNF-α were analyzed by ELISA. ## p < 0.01 versus Ctrl; ** p < 0.01 versus Model.

Article Snippet: CD206 (A02285-2) and CD86 (BM4121) were purchased from Boster Biological Technology Co., LTD (Wuhan, China).

Techniques: Staining, Immunofluorescence, Enzyme-linked Immunosorbent Assay

Journal: BioMed Research International

Article Title: Effect of Wnt Signaling on the Differentiation of Islet β -Cells from Adipose-Derived Stem Cells

doi: 10.1155/2017/2501578

Figure Lengend Snippet: Immunostaining of rat ADSCs, rat ADSCs induced into insulin-producing cells, and rat PASCs. (a–e) CD13, CD44, CD49d, CD106, and control group (no primary antibody) staining of rat ADSCs. (f–j) PDX1, nestin, CK19, insulin, and control group staining of rat ADSCs induced into insulin-producing cells. (k–o) PDX1, nestin, CK19, insulin, and control group staining of rat PASCs. Magnification: ×100.

Article Snippet: CD13 (BA0718), CD44 (BA0321), CD106 (BA0406), and CD49d (BA1640) antibodies were from Boster Biological (Wuhan, China).

Techniques: Immunostaining, Control, Staining

Journal: Frontiers in Nutrition

Article Title: Prevention of high-fat/high-sugar diet-induced type 2 diabetes mellitus-associated non-alcoholic fatty liver disease in rats with fermented and raw Rosa roxburghii Tratt (Cili) juice

doi: 10.3389/fnut.2025.1584551

Figure Lengend Snippet: Expression analyses of transcription or protein levels of selected genes. (A) Expression analyses of selected genes by qRT–PCR. The data represent the means ± SDs from six biological replicates with three technical replicates. (B–D) FCJ/RCJ upregulated ABCC3, IDI1, and APOA2 expression in the liver. FCJ and RCJ significantly upregulated hepatic ABCC3 (B) and IDI1 (C) expression, and RCJ significantly upregulated hepatic APOA2 (D) expression in T2DM rats. The data represent the means ± SDs from three biological replicates with three technical replicates. * p < 0.05, *** p < 0.001, **** p < 0.0001.

Article Snippet: The western blotting antibodies used included APOA2 (BM5624, BOSTER, China), IDI1 (A07892-1, BOSTER, China), ABCC3 (DF3874, Affinity, United States), β-tubulin (Solarbio, China), goat anti-rabbit (BS13278, Bioworld, United States), and goat anti-mouse (BS12478, Bioworld, United States) antibodies.

Techniques: Expressing, Quantitative RT-PCR

Journal: Frontiers in Physiology

Article Title: Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats

doi: 10.3389/fphys.2019.01169

Figure Lengend Snippet: Schematic representation of the renin angiotensin system (RAS) showing the pathways responsible for the generation of angiotensin II (Ang II) and angiotensin-(1-7) [Ang-(1-7)]. Ang II acts via its type 1 receptor (AT1R) to exert vasoconstrictive effects. Ang II is degraded to Ang-(1-7) by angiotensin converting enzyme 2 (ACE2). Ang-(1-7) opposes Ang II effects through its receptors, MasR and MrgD.

Article Snippet: Primary monoclonal antibodies for MasR (Alomone labs, Israel) and MrgD (Alomone labs, Israel) were used at 1:500 and 1:400 dilutions, respectively.

Techniques:

Journal: Frontiers in Physiology

Article Title: Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats

doi: 10.3389/fphys.2019.01169

Figure Lengend Snippet: Changes in portal pressure (PP) after intravenous bolus injections of either the MasR blocker A779 (10 μg/kg), MrgD blocker D-Pro (10 μg/kg), or AT2R blocker PD123319 (1 mg/kg) in CCl 4 (A) , BDL (B) , and PPVL (C) models. Saline injection served as the control. Pressure measurement was commenced 5 min prior to injection and continued for 30 min after the injection. Each time point represents the mean ± SEM profile from six to seven rats per treatment group. **** p < 0.05, ** p < 0.01, * p < 0.05 baseline vs. A779, #### p < 0.05, ### p < 0.005, # p < 0.05 baseline vs. D-Pro, θθθθ p < 0.05, θθθ p < 0.01, θ p < 0.05 baseline vs. PD123319.

Article Snippet: Primary monoclonal antibodies for MasR (Alomone labs, Israel) and MrgD (Alomone labs, Israel) were used at 1:500 and 1:400 dilutions, respectively.

Techniques: Injection

Journal: Frontiers in Physiology

Article Title: Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats

doi: 10.3389/fphys.2019.01169

Figure Lengend Snippet: Changes in mean arterial pressure (MAP) with intravenous bolus injections of either MasR blocker A779 (10 μg/kg), MrgD blocker D-Pro (10 μg/kg) or AT2R blocker PD123319 (1 mg/kg) in CCl 4 (A) BDL (B) , and PPVL (C) models. Saline injection served as the control. Each time point represents the mean ± SEM profile from six to seven rats per treatment group. * p < 0.05 baseline vs. A779; ## p < 0.01, # p < 0.05, baseline vs. D-Pro.

Article Snippet: Primary monoclonal antibodies for MasR (Alomone labs, Israel) and MrgD (Alomone labs, Israel) were used at 1:500 and 1:400 dilutions, respectively.

Techniques: Injection

Journal: Frontiers in Physiology

Article Title: Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats

doi: 10.3389/fphys.2019.01169

Figure Lengend Snippet: Changes in mean arterial pressure after the treatment with AT1R blocker losartan (1 mg/kg) in the CCl 4 (A) and BDL (B) models. Note that the two groups that received losartan injections in each model were pooled for t-test analysis. Bottom panels show mean arterial pressure of the two losartan groups after receiving either MasR blocker A779 (10 μg/kg) or MrgD blocker D-Pro (10 μg/kg) in the CCl 4 (C) and BDL (D) models. Losartan significantly reduced MAP in all groups; however, A779 or D-Pro which was given 20 min after losartan failed to counteract the hypotensive effect of losartan. Each time point represents the mean ± SEM profile from 12 to 14 (A,B) or 6 to 7 (C,D) rats per treatment group. Data in (C) and (D) were analyzed by repeated-measures ANOVA. ** p < 0.01, *** p < 0.001, **** p < 0.0005 baseline vs. post-losartan injection.

Article Snippet: Primary monoclonal antibodies for MasR (Alomone labs, Israel) and MrgD (Alomone labs, Israel) were used at 1:500 and 1:400 dilutions, respectively.

Techniques: Injection

Journal: Frontiers in Physiology

Article Title: Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats

doi: 10.3389/fphys.2019.01169

Figure Lengend Snippet: Changes in portal pressure after the treatment with AT1R blocker losartan (1 mg/kg) in the CCl 4 (A) and BDL (B) models. Note that the two groups that received losartan injections in each model were pooled for t -test analysis. Bottom panels show portal pressure of the two losartan groups after receiving either MasR blocker A779 (10 μg/kg) or MrgD blocker D-Pro (10 μg/kg) in the CCl 4 (C) and BDL (D) models. Losartan significantly reduced portal pressure in all groups; however, A779 or D-Pro which was given 20 min after losartan failed to affect portal pressure. Each time point represents the mean ± SEM profile from 12 to 14 (A,B) or 6 to 7 (C,D) rats per treatment group. Data in (C) and (D) were analyzed by repeated-measures ANOVA. ** p < 0.01, *** p < 0.001, **** p < 0.0005 baseline vs. post-losartan injection.

Article Snippet: Primary monoclonal antibodies for MasR (Alomone labs, Israel) and MrgD (Alomone labs, Israel) were used at 1:500 and 1:400 dilutions, respectively.

Techniques: Injection

Journal: Frontiers in Physiology

Article Title: Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats

doi: 10.3389/fphys.2019.01169

Figure Lengend Snippet: Receptor gene expression of MasR (A) , MrgD (B) , and AT1R (C) analyzed by qPCR in mesenteric vascular bed of the CCl 4 , BDL and PPVL rats compared with sham-operated and healthy control rats. Data have been normalized to endogenous control gene 18S, and healthy control group was given an arbitrary value of 1. Each time point represents the mean ± SEM profile from six to seven rats per treatment group.

Article Snippet: Primary monoclonal antibodies for MasR (Alomone labs, Israel) and MrgD (Alomone labs, Israel) were used at 1:500 and 1:400 dilutions, respectively.

Techniques: Expressing

Journal: Frontiers in Physiology

Article Title: Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats

doi: 10.3389/fphys.2019.01169

Figure Lengend Snippet: Receptor gene expression of MasR (A) , MrgD (B) , and AT1R (C) analyzed by qPCR in the livers of the CCl 4 , BDL, and PPVL rats compared with sham-operated and healthy control rats. Data have been normalized to endogenous control gene 18S, and healthy control group was given an arbitrary value of 1. Each time point represents the mean ± SEM profile from six to seven rats per treatment group.

Article Snippet: Primary monoclonal antibodies for MasR (Alomone labs, Israel) and MrgD (Alomone labs, Israel) were used at 1:500 and 1:400 dilutions, respectively.

Techniques: Expressing

Journal: Frontiers in Physiology

Article Title: Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats

doi: 10.3389/fphys.2019.01169

Figure Lengend Snippet: Immunohistochemical localization of MasR (left column) and MrgD (right column) in the liver. MasR (C) and MrgD (D) staining of CCl 4 livers were compared with those of healthy control livers ( A,B , respectively). Note that in cirrhotic livers (C) , there was strong positive staining for MasR in liver sinusoids (arrow) which is consistent with the localization of hepatic stellate cells and/or liver sinusoidal endothelial cells. Also note that positive staining for MasR in bile duct epithelial cells (arrow head-large) and hepatic arterioles (arrow head-small) in the cirrhotic liver. However, there was no positive staining for MrgD in the cirrhotic liver (D) . Livers from PPVL rats showed no positive staining for both receptors (G,H) compared to the controls (E,F) . Original images were captured at the X20 magnification.

Article Snippet: Primary monoclonal antibodies for MasR (Alomone labs, Israel) and MrgD (Alomone labs, Israel) were used at 1:500 and 1:400 dilutions, respectively.

Techniques: Immunohistochemical staining, Staining